ABSTRACT
La prevalencia de Esquizofrenia es muy baja en la infancia y adolescencia temprana, aumentando en la adolescencia y adultez a un 1%. Se ha estimado que la prevalencia de psicosis de 0,9 en 10.000 a los 13 años y 17,6 en 10.000 a los 18 años. Los cuadros esquizofrénicos de inicio temprano y muy temprano son una variante severa del trastorno y se asocian a un mayor deterioro funcional, curso clínico más grave y peor evolución. Todo esto determina la necesidad de implementar tratamientos multimodales tempranos y eficaces, así como estrategias preventivas en los grupos de mayor riesgo. El tratamiento farmacológico cuenta con mayores evidencias de efectividad en este cuadro y otorga notables beneficios a los pacientes, sin embargo se requiere mayor investigación a largo plazo respecto a los efectos adversos secundarios, su impacto en individuos en desarrollo y la eficacia de estos agentes. Estos avances permitirán al clínico establecer un justo balance costo/beneficio de su uso en población infantojuvenil.
The prevalence of schizophrenia is very low during childhood and early adolescence, increasing later in adolescence and adulthood to 1%. It has been established that the prevalence of psychosis is 0.9/10000 at 13 years of age and 17.6/10000 at 18 years of age. Early and very early onset schizophrenia are a severe form of this disorder, and are associated to a larger disability, more severe form of the disease and worse prognosis. These factors determine the need of implementing treatments that are multimodal, early and effective, as well as preventive strategies in high risk groups. The pharmacological treatment of schizophrenia has evidence of effectiveness and gives patients important benefits, however, more long term research is needed regarding its side effects, its impact on the developing brain and its effectiveness. These facts would help the psychiatrist to establish the value, risks and benefits of the use of drugs in children and adolescents.
Subject(s)
Humans , Child , Adolescent , Psychotic Disorders/therapy , Schizophrenia/therapy , Psychotic Disorders/prevention & control , Psychotic Disorders/drug therapy , Schizophrenia/prevention & control , Schizophrenia/drug therapy , Antipsychotic Agents/therapeutic useABSTRACT
The identification of biological markers of Alzheimer's disease (AD) can be extremely useful to improve diagnostic accuracy and/or to monitor the efficacy of putative therapies. In this regard, peripheral cells may be of great importance, because of their easy accessibility. After subjects were grouped according to diagnosis, the expression of conformationally mutant p53 in blood cells was compared by immunoprecipitation or by a cytofluorimetric assay. In total, 104 patients with AD, 92 age-matched controls, 15 patients with Parkinson's disease and 9 with other types of dementia were analyzed. Two independent methods to evaluate the differential expression of a conformational mutant p53 were developed. Mononuclear cells were analyzed by immunoprecipitation or by flow-cytometric analysis, following incubation with a conformation-specific p53 antibody, which discriminates unfolded p53 tertiary structure. Mononuclear cells from AD patients express a higher amount of mutant-like p53 compared to non-AD subjects, thus supporting the study of conformational mutant p53 as a new putative marker to discriminate AD from non-AD patients. We also observed a strong positive correlation between the expression of p53 and the age of patients. The expression of p53 was independent from the length of illness and from the Mini Mental State Examination value.
Subject(s)
Alzheimer Disease/genetics , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/genetics , Aged , Aged, 80 and over , Aging/genetics , DNA/blood , DNA/genetics , DNA/isolation & purification , Dementia/blood , Dementia/genetics , Flow Cytometry , Humans , Italy , Leukocytes , Parkinson Disease/blood , Parkinson Disease/genetics , Poland , Protein Conformation , Reference Values , Tumor Suppressor Protein p53/bloodABSTRACT
This study concerned a group of ex-workers (372 males and 99 females) from a firm situated in Bergamo (Italy) that ceased its activity at the beginning of the Nineties. From an introductory analysis of the results, we found out that there isn't excess in the death-rate for liver and bile ducts cancers among the males of this group. Among them, for what concerns the other tumoral pathologies, such as leukaemia and stomach tumors, the information allowed to verify an excess of mortality. However, this increase hasn't result statistically significant. On the contrary, it came out that there is an excess of risk for intestine tumors: standardized death-rate of 2.58. In accordance with the information collected, for the future it will be necessary to carefully examine the research in order to verify the existence of a direct connection to the exposure at PCB and study the incidence (not only for mortality) of these neoplasms.
